1.Review current limited data evaluating VTE risk of contraceptive and therapeutic progestins in contrast to combined hormonal contraception.
2. Identify best practices in reporting on pharmacoepidemiology studies using routinely collected health data with rare exposures and rare outcomes.
3. Learn about preliminary results from a nested case-control study to determine risk estimates for incident acute VTE associated with the use of progestin-only medications by women of reproductive age as compared with non-use.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation